The regulatory framework for radiopharmaceuticals is often a complex process as they have a set of differentiating characteristics from “conventional” medicines.
In this editions, we invited Dra. Olga Calado, Technical Director of ICNAS Pharma, to answer some questions that will help us to reflect on this topic. We would like to thank you for your willingness and kindness to participate in this challenge that makes this month one year.
Don’t miss the opportunity to read it!